For NK cells, one study showed the overexpression of CXCR4, a chemokine receptor commonly found on NK cells, together with a CD19-specific CAR [45], raising hopes that such double gene-edit may also yield enhanced efficacy of cell therapies in other cancer types. The gene discussed is CD19; the disease is cancer.